Aberdeen Group plc Has $10.87 Million Stock Holdings in LivaNova PLC $LIVN

Key Points

• Aberdeen Group plc increased its stake in LivaNova PLC by 19.3%, acquiring 44,685 shares, which brought its total holdings to 276,710 shares valued at approximately $10.87 million.
• LivaNova reported an earnings per share (EPS) of $1.05 for the quarter, surpassing analyst expectations of $0.84 and reflecting a 10.6% year-over-year revenue increase.
• Several analysts have upgraded LivaNova's stock rating, with a consensus target price of $59.29, indicating a generally positive outlook among analysts.

Aberdeen Group plc increased its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 19.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 276,710 shares of the company's stock after acquiring an additional 44,685 shares during the period. Aberdeen Group plc owned about 0.51% of LivaNova worth $10,869,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of LIVN. Nuveen LLC purchased a new stake in shares of LivaNova during the 1st quarter worth about $30,954,000. Freestone Grove Partners LP acquired a new position in LivaNova in the fourth quarter worth approximately $23,102,000. The Manufacturers Life Insurance Company raised its position in LivaNova by 163.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 546,387 shares of the company's stock valued at $25,303,000 after acquiring an additional 339,139 shares in the last quarter. AQR Capital Management LLC lifted its stake in LivaNova by 79.3% in the fourth quarter. AQR Capital Management LLC now owns 742,180 shares of the company's stock valued at $34,214,000 after acquiring an additional 328,313 shares during the last quarter. Finally, LSV Asset Management grew its position in LivaNova by 278.3% in the first quarter. LSV Asset Management now owns 438,498 shares of the company's stock worth $17,224,000 after acquiring an additional 322,598 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

LivaNova Stock Performance

NASDAQ LIVN traded up $0.45 during trading on Monday, hitting $56.35. The company's stock had a trading volume of 933,245 shares, compared to its average volume of 821,975. The company has a quick ratio of 1.09, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. The firm has a 50 day moving average price of $46.64 and a 200 day moving average price of $43.06. The firm has a market cap of $3.08 billion, a P/E ratio of -14.49 and a beta of 0.92. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $57.35.

LivaNova (NASDAQ:LIVN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $1.05 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.21. The company had revenue of $352.50 million during the quarter, compared to analysts' expectations of $332.20 million. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.LivaNova's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.93 earnings per share. Equities research analysts forecast that LivaNova PLC will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LIVN has been the topic of a number of recent research reports. Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price target on the stock in a report on Tuesday, May 20th. Needham & Company LLC restated a "buy" rating and set a $64.00 target price on shares of LivaNova in a report on Tuesday, May 13th. Barclays boosted their price target on LivaNova from $55.00 to $58.00 and gave the stock an "equal weight" rating in a research report on Thursday. Robert W. Baird increased their price objective on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Finally, Wall Street Zen upgraded LivaNova from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $59.71.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.